AA Joy
Ontario Institute for Cancer Research · 6 works · 25 citations · h-index 2
Top works
- Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)
- Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies
- Abstract PD05-04: The Potential of Using Discordance of Estrogen PET (FES-PET) and Glucose PET (FDG-PET) Scans and Pathologic Characteristics Including HER2 and Ki67 To Predict for Hormone Insensitivity in Women with Metastatic Breast Cancer
- Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2
- Abstract P4-22-10: Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc
- Abstract P4-13-06: Real-world experience using exemestane and everolimus in patients with hormone receptor positive/HER2 negative breast cancer with and without prior CDK4/6 inhibitor exposure